COMMUNIQUÉS West-GlobeNewswire

-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16/04/2024 -
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16/04/2024 -
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
16/04/2024 -
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16/04/2024 -
Faron Confirms Plans for the Coming Months Under New Leadership
16/04/2024 -
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
16/04/2024 -
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16/04/2024 -
StateHouse Appoints Felicia Snyder as Independent Chair of the Board
16/04/2024 -
Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month
16/04/2024 -
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
16/04/2024 -
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15/04/2024 -
AVITA Medical to Announce First Quarter 2024 Financial Results
15/04/2024 -
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
15/04/2024 -
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
15/04/2024 -
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
15/04/2024 -
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
15/04/2024 -
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
15/04/2024 -
Theratechnologies annonce l’envoi de sa circulaire de sollicitation de procurations en vue de l’assemblée annuelle des actionnaires
15/04/2024 -
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
15/04/2024
Pages